Jiangxi Fushine Pharmaceutical Co Ltd Market Cap ($1.08 Billion)
Market Cap & Net Worth: Jiangxi Fushine Pharmaceutical Co Ltd (300497)
Jiangxi Fushine Pharmaceutical Co Ltd market cap. Jiangxi Fushine Pharmaceutical Co Ltd (SHE:300497) has a market capitalization of $1.08 Billion (CN¥7.40 Billion) as of November 8, 2026. Listed on the SHE stock exchange, this China-based company holds position #8260 globally and #1877 in its home market, demonstrating a 1.40% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jiangxi Fushine Pharmaceutical Co Ltd's stock price CN¥13.73 by its total outstanding shares 538648934 (538.65 Million). Also see 300497 cash flow metrics for how efficiently the company converts equity into cash flow.
Jiangxi Fushine Pharmaceutical Co Ltd Market Cap History (2015–2026)
Jiangxi Fushine Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows growth from $553.17 Million to $1.08 Billion (13.09% CAGR). Check Jiangxi Fushine Pharmaceutical Co Ltd (300497) share price today for real-time trading data and today's change.
Jiangxi Fushine Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jiangxi Fushine Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Jiangxi Fushine Pharmaceutical Co Ltd (300497) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.01x
Jiangxi Fushine Pharmaceutical Co Ltd's market cap is 1.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.13 Billion | $763.69 Million | $173.91 Million | 1.48x | 6.50x |
| 2017 | $713.50 Million | $958.15 Million | $177.55 Million | 0.74x | 4.02x |
| 2018 | $720.18 Million | $1.16 Billion | $194.72 Million | 0.62x | 3.70x |
| 2019 | $908.53 Million | $1.35 Billion | $305.84 Million | 0.67x | 2.97x |
| 2020 | $1.11 Billion | $1.49 Billion | $319.30 Million | 0.74x | 3.47x |
| 2021 | $1.29 Billion | $1.43 Billion | $48.83 Million | 0.90x | 26.36x |
| 2022 | $1.04 Billion | $1.65 Billion | -$141.47 Million | 0.63x | N/A |
| 2023 | $737.77 Million | $1.61 Billion | -$200.80 Million | 0.46x | N/A |
| 2024 | $657.37 Million | $1.18 Billion | -$272.10 Million | 0.56x | N/A |
| 2025 | $1.19 Billion | $1.18 Billion | -$53.07 Million | 1.01x | N/A |
Competitor Companies of 300497 by Market Capitalization
Companies near Jiangxi Fushine Pharmaceutical Co Ltd in the global market cap rankings as of November 8, 2026. Also see 300497 total asset value for a full breakdown of the balance sheet.
Key companies related to Jiangxi Fushine Pharmaceutical Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Jiangxi Fushine Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Jiangxi Fushine Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Jiangxi Fushine Pharmaceutical Co Ltd's market cap moved from $553.17 Million to $ 1.08 Billion, with a yearly change of 13.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.08 Billion | -9.13% |
| 2025 | CN¥1.19 Billion | +81.18% |
| 2024 | CN¥657.37 Million | -10.90% |
| 2023 | CN¥737.77 Million | -29.09% |
| 2022 | CN¥1.04 Billion | -19.17% |
| 2021 | CN¥1.29 Billion | +16.29% |
| 2020 | CN¥1.11 Billion | +21.83% |
| 2019 | CN¥908.53 Million | +26.15% |
| 2018 | CN¥720.18 Million | +0.94% |
| 2017 | CN¥713.50 Million | -36.84% |
| 2016 | CN¥1.13 Billion | +104.22% |
| 2015 | CN¥553.17 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Jiangxi Fushine Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.08 Billion USD |
| MoneyControl | $1.08 Billion USD |
| MarketWatch | $1.08 Billion USD |
| marketcap.company | $1.08 Billion USD |
| Reuters | $1.08 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jiangxi Fushine Pharmaceutical Co Ltd
Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. It offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride dispersi… Read more